Skip to main content
Top

06-07-2024 | Psoriatic Arthritis | Review

Core items to be included in a definition of moderate psoriatic arthritis: literature review and expert opinion

Authors: Ana Urruticoechea-Arana, José Luis Álvarez-Vega, Maria Luz García-Vivar, José Antonio Pinto-Tasende, María Jesús García de Yébenes, Loreto Carmona, Rubén Queiro

Published in: Rheumatology International

Login to get access

Abstract

Evidence-based treatment recommendations for psoriatic arthritis (PsA) suggest that treatment should be individualised but acknowledge the difficulty of correctly defining levels of activity (mild, moderate and severe). The aim of this study was to define the parameters or disease characteristics that should be included in a future definition of moderate PsA. Mixed. methods: (1) literature review to identify previous assessment tools used to classify patients into mild, moderate and severe forms, and (2) survey of rheumatologists, and experts in PsA, to obtain their opinion on the degree of validation and applicability of published definitions and tools, and on the parameters that should be included in a future definition of moderate PsA. We propose eight domains/items to be included in a definition of moderate PsA: number of active joints and inflamed entheses, physician global assessment (by visual analogue scale), dactylitis, body surface area (BSA) affected by psoriasis, psoriasis in special locations, and absence of hip involvement. The Disease Activity Index for Psoriatic Arthritis (DAPSA) score would be supported as part of this definition, as would the Psoriatic Arthritis Impact of Disease (PsAID) index. This study proposes a set of items/domains to be included in a definition of moderate PsA based on literature and expert opinion, which can be the starting point for further development and validation studies of the proposed items.
Appendix
Available only for authorised users
Literature
12.
go back to reference Haddaway NRAUPCC, McGuinness LA (2021) PRISMA2020: R package and ShinyApp for producing PRISMA 2020 compliant flow diagrams (Version 0.0.2). Zenodo Haddaway NRAUPCC, McGuinness LA (2021) PRISMA2020: R package and ShinyApp for producing PRISMA 2020 compliant flow diagrams (Version 0.0.2). Zenodo
17.
go back to reference Kulkarni AS, Horn E, Balkrishnan R, Feldman S (eds) Severity levels in psoriasis: a separate ‘very severe’ category not required. J Dermatol Treat. 1 ed. England 2009. pp. 48–51 Kulkarni AS, Horn E, Balkrishnan R, Feldman S (eds) Severity levels in psoriasis: a separate ‘very severe’ category not required. J Dermatol Treat. 1 ed. England 2009. pp. 48–51
18.
go back to reference American Academy of Dermatology, Work G, Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM et al (2011) Guidelines of care for the management of psoriasis and psoriatic arthritis: Sect. 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 65(1):137–174. https://doi.org/10.1016/j.jaad.2010.11.055CrossRef American Academy of Dermatology, Work G, Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM et al (2011) Guidelines of care for the management of psoriasis and psoriatic arthritis: Sect. 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 65(1):137–174. https://​doi.​org/​10.​1016/​j.​jaad.​2010.​11.​055CrossRef
24.
go back to reference EMEA. Committee for medical products for human use of EMEA Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. European Medicines Agency Evaluation of Medicines for Human use, UEMEA/CHMP/EWP/2454/02 2004 [Available from: http://www.euma.europa.eu/ EMEA. Committee for medical products for human use of EMEA Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis. European Medicines Agency Evaluation of Medicines for Human use, UEMEA/CHMP/EWP/2454/02 2004 [Available from: http://​www.​euma.​europa.​eu/​
26.
go back to reference Helliwell PS, Deodhar A, Gottlieb AB, Boehncke WH, Xu XL, Xu S et al (2020) Composite measures of Disease Activity in Psoriatic Arthritis: comparative instrument performance based on the efficacy of Guselkumab in an interventional phase II trial. Arthritis Care Res (Hoboken) 72(11):1579–1588. https://doi.org/10.1002/acr.24046CrossRefPubMed Helliwell PS, Deodhar A, Gottlieb AB, Boehncke WH, Xu XL, Xu S et al (2020) Composite measures of Disease Activity in Psoriatic Arthritis: comparative instrument performance based on the efficacy of Guselkumab in an interventional phase II trial. Arthritis Care Res (Hoboken) 72(11):1579–1588. https://​doi.​org/​10.​1002/​acr.​24046CrossRefPubMed
38.
go back to reference Mease PJ, Gladman DD, Ogdie A, Coates LC, Behrens F, Kavanaugh A et al (2020) Treatment-to-target with apremilast in psoriatic arthritis: the probability of achieving targets and Comprehensive Control of Disease manifestations. Arthritis Care Res (Hoboken) 72(6):814–21. https://doi.org/10.1002/acr.24134.CrossRefPubMed Mease PJ, Gladman DD, Ogdie A, Coates LC, Behrens F, Kavanaugh A et al (2020) Treatment-to-target with apremilast in psoriatic arthritis: the probability of achieving targets and Comprehensive Control of Disease manifestations. Arthritis Care Res (Hoboken) 72(6):814–21. https://​doi.​org/​10.​1002/​acr.​24134.CrossRefPubMed
40.
go back to reference Mulder MLM, van Hal TW, van den Hoogen FHJ, de Jong E, Vriezekolk JE, Wenink MH (2020) Measuring disease activity in psoriatic arthritis: PASDAS implementation in a tightly monitored cohort reveals residual disease burden. Rheumatology (Oxford). 00, https://pubmed.ncbi.nlm.nih.gov/33331947/ Mulder MLM, van Hal TW, van den Hoogen FHJ, de Jong E, Vriezekolk JE, Wenink MH (2020) Measuring disease activity in psoriatic arthritis: PASDAS implementation in a tightly monitored cohort reveals residual disease burden. Rheumatology (Oxford). 00, https://​pubmed.​ncbi.​nlm.​nih.​gov/​33331947/​
43.
go back to reference Coates LC, Mumtaz A, Helliwell PS, Mease PJ, Callis-Duffin K, Krueger GG et al (eds) (2011) Development of a disease severity and responder index for psoriatic arthritis (PsA)--report of the OMERACT 10 PsA special interest group. J Rheumatol; Canada Coates LC, Mumtaz A, Helliwell PS, Mease PJ, Callis-Duffin K, Krueger GG et al (eds) (2011) Development of a disease severity and responder index for psoriatic arthritis (PsA)--report of the OMERACT 10 PsA special interest group. J Rheumatol; Canada
46.
go back to reference Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH et al (eds) (2009) Treatment recommendations for psoriatic arthritis. Ann Rheum Dis Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH et al (eds) (2009) Treatment recommendations for psoriatic arthritis. Ann Rheum Dis
51.
go back to reference Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY et al (eds) (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: Sect. 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol; United States Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY et al (eds) (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: Sect. 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol; United States
52.
Metadata
Title
Core items to be included in a definition of moderate psoriatic arthritis: literature review and expert opinion
Authors
Ana Urruticoechea-Arana
José Luis Álvarez-Vega
Maria Luz García-Vivar
José Antonio Pinto-Tasende
María Jesús García de Yébenes
Loreto Carmona
Rubén Queiro
Publication date
06-07-2024
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-024-05644-y
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare